Researchers systematically consulted the Massachusetts General Hospital fracture liaison service for patients admitted to the orthopedics service with fragility fracture between February 2016 and ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

Zoledronic acid therapy reduced the risk of morphometric vertebral fractures among men with osteoporosis in a multicentre, double-blind, placebo-controlled trial. Patients with primary or hypogonadism ...

Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

Older women with osteoporosis who received yearly infusions of a drug that prevents bone loss had far fewer fractures than did peers who didn’t get the drug. Over 3 years, the women who received ...

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a ...

One annual infusion of zoledronic acid (Reclast) significantly reduces fracture risk in postmenopausal women with osteoporosis, according to results of a major trial. An international group of ...

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the mechanisms of action of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic ...

Imagine going to the doctor’s office once a year for treatment of a chronic medical condition. No daily pills. No weekly therapies. Just 30 minutes or so in a clinic. It could happen. A new ...

Gonadotropin-releasing-hormone (GnRH) agonists are routinely used to manage recurrent nonmetastatic prostate cancer, but the therapy results in hypogonadism, which has adverse consequences including ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone ...